J&J cuts 80 execs from middle ranks in India

Johnson & Johnson's Indian operations has laid off 80 middle managers since January as part of a global, companywide restructuring, India's Economic Times reports. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.